دورية أكاديمية
أعرض في EDS

Phospholipid metabolism-related genotypes of PLA2R1 and CERS4 contribute to nonobese MASLD.

التفاصيل البيبلوغرافية
العنوان: Phospholipid metabolism-related genotypes of PLA2R1 and CERS4 contribute to nonobese MASLD.
المؤلفون: Shao C; Department of Gastroenterology of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Ye J; Department of Gastroenterology of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Dong Z; Department of Radiology of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Liao B; Department of Pathology of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Feng S; Department of Radiology of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Hu S; Department of Gastroenterology of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.; Department of Precision Medicine, Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China., Zhong B; Department of Gastroenterology of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
المصدر: Hepatology communications [Hepatol Commun] 2024 Jun 05; Vol. 8 (6). Date of Electronic Publication: 2024 Jun 05 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 101695860 Publication Model: eCollection Cited Medium: Internet ISSN: 2471-254X (Electronic) Linking ISSN: 2471254X NLM ISO Abbreviation: Hepatol Commun Subsets: MEDLINE
أسماء مطبوعة: Publication: 2023- : [Philadelphia] : Wolters Kluwer Health, Inc.
Original Publication: [Hoboken, NJ] : Wiley Periodicals, Inc. on behalf of the American Association for the Study of Liver Diseases, [2017]-
مواضيع طبية MeSH: Genotype* , Receptors, Phospholipase A2*/genetics, Humans ; Male ; Female ; Middle Aged ; Case-Control Studies ; Phospholipids/blood ; Adult ; Obesity/genetics ; Polymorphism, Single Nucleotide ; Fatty Liver/genetics ; Genetic Predisposition to Disease/genetics
مستخلص: Background: Abnormal phospholipid metabolism is linked to metabolic dysfunction-associated steatotic liver disease (MASLD) development and progression. We aimed to clarify whether genetic variants of phospholipid metabolism modify these relationships.
Methods: This case-control study consecutively recruited 600 patients who underwent MRI-based proton density fat fraction examination (240 participants with serum metabonomics analysis, 128 biopsy-proven cases) as 3 groups: healthy control, nonobese MASLD, and obese MASLD, (n = 200 cases each). Ten variants of phospholipid metabolism-related genes [phospholipase A2 Group VII rs1805018, rs76863441, rs1421378, and rs1051931; phospholipase A2 receptor 1 (PLA2R1) rs35771982, rs3828323, and rs3749117; paraoxonase-1 rs662 and rs854560; and ceramide synthase 4 (CERS4) rs17160348)] were genotyped using SNaPshot.
Results: The T-allele of CERS4 rs17160348 was associated with a higher risk of both obese and nonobese MASLD (OR: 1.95, 95% CI: 1.20-3.15; OR: 1.76, 95% CI: 1.08-2.86, respectively). PLA2R1 rs35771982-allele is a risk factor for nonobese MASLD (OR: 1.66, 95% CI: 1.11-1.24), moderate-to-severe steatosis (OR: 3.24, 95% CI: 1.96-6.22), and steatohepatitis (OR: 2.61, 95% CI: 1.15-3.87), while the paraoxonase-1 rs854560 T-allele (OR: 0.50, 95% CI: 0.26-0.97) and PLA2R1 rs3749117 C-allele (OR: 1.70, 95% CI: 1.14-2.52) are closely related to obese MASLD. After adjusting for sphingomyelin level, the effect of the PLA2R1 rs35771982CC allele on MASLD was attenuated. Furthermore, similar effects on the association between the CERS4 rs17160348 C allele and MASLD were observed for phosphatidylcholine, phosphatidic acid, sphingomyelin, and phosphatidylinositol.
Conclusions: The mutations in PLA2R1 rs35771982 and CERS4 rs17160348 presented detrimental impact on the risk of occurrence and disease severity in nonobese MASLD through altered phospholipid metabolism.
(Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.)
References: Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatol. 2023;78:1966–1986.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896–904.
Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol. 2021;36:1497–1507.
Shao C, Ye J, Li F, Lin Y, Wu T, Wang W, et al. Early predictors of cardiovascular disease risk in nonalcoholic fatty liver disease: Non-obese versus obese patients. Dig Dis Sci. 2020;65:1850–1860.
Shao C, Ye J, Li F, Feng S, Wang W, Zhong B. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2019;51:1392–1399.
Sookoian S, Pirola. CJ. Systematic review with meta-analysis: Risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46:85–95.
Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–1465.
Musso G, Cassader M, Bo S, De Michieli F, Gambino R. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes. 2013;62:1109–1120.
Goffredo M, Caprio S, Feldstein AE, D’Adamo E, Shaw MM, Pierpont B, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology. 2016;63:117–125.
Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2013;52:175–191.
Valenti L, Nobili V. S. Fargion. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;363:194–195.
Hall Z, Bond NJ, Ashmore T, Sanders F, Ament Z, Wang X, et al. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease. Hepatology. 2017;65:1165–1180.
Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 2006;3:321–331.
Maiolino G, Lenzini L, Pedon L, Cesari M, Seccia TM, Frigo AC, et al. Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease. J Cardiovasc Med (Hagerstown). 2015;16:29–36.
Qi Y, Zhao D, Jia Z, Wang W, Wang M, Sun J, et al. A previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein-associated phospholipase A2 activity and mass. Sci Rep. 2016;6:37465.
Si NV, Fujioka D, Watanabe K, Watanabe Y, Watanabe K, Nakamura K, et al. Phospholipase A(2) receptor gene polymorphisms alter its functions and present a genetic risk of an increased intima-media thickness of the carotid artery. J Atheroscler Thromb. 2016;23:1227–1241.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–209.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.
Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919.
Dong Z, Luo Y, Zhang Z, Cai H, Li Y, Chan T, et al. MR quantification of total liver fat in patients with impaired glucose tolerance and healthy subjects. PLoS ONE. 2014;9:e111283.
Ye J, Hu X, Wu T, Wu Y, Shao C, Li F, et al. Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: A cross-sectional study. Diabetol Metab Syndr. 2019;11:45.
Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis. Eur Radiol. 2019;29:3564–3573.
Imajo K, Honda Y, Kobayashi T, Nagai K, Ozaki A, Iwaki M, et al. Direct comparison of US and MR Elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20:908–917.
Herrmann E, de Lédinghen V, Cassinotto C, Chu WC, Leung VY, Ferraioli G, et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis. Hepatology. 2018;67:260–272.
Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism. 2016;65:1080–1086.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
Shao C, Xu L, Lei P, Wang W, Feng S, Ye J, et al. Metabolomics to identify fingerprints of carotid atherosclerosis in nonobese metabolic dysfunction-associated fatty liver disease. J Transl Med. 2023;21:12.
García-Heredia A, Kensicki E, Mohney RP, Rull A, Triguero I, Marsillach J, et al. Paraoxonase-1 deficiency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet: A metabolomic approach. J Proteome Res. 2013;12:1946–1955.
Meneses MJ, Silvestre R, Sousa-Lima I, Macedo MP. Paraoxonase-1 as a regulator of glucose and lipid homeostasis: Impact on the onset and progression of metabolic disorders. Int J Mol Sci. 2019;20:4049.
Milaciu MV, Vesa ȘC, Bocșan IC, Ciumărnean L, Sâmpelean D, Negrean V, et al. Paraoxonase-1 serum concentration and PON1 gene polymorphisms: Relationship with non-alcoholic fatty liver disease. J Clin Med. 2019;8:2200.
Hanasaki K, Arita H. Phospholipase A2 receptor: A regulator of biological functions of secretory phospholipase A2 Prostaglandins Other Lipid Mediat. 2002;68-69:71–A82.
Murakami M, Taketomi Y, Miki Y, Sato H, Hirabayashi T, Yamamoto K. Recent progress in phospholipase A 2 research: From cells to animals to humans. Prog Lipid Res. 2011;50:152–192.
Dai H, Zhang H, He. Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: An updated meta-analysis. Sci Rep. 2015;5:8803.
Liu X, Xu W, Yu C, Wang M, Liu R, Xie R. Associations between m-type phospholipase A2 receptor, human leukocyte antigen gene polymorphisms and idiopathic membranous nephropathy. Bioengineered. 2021;12:8833–8844.
Tian CX, Li L, Qiu P, Qiu YR. Association of SNPs in PLA2R1 with idiopathic and secondary membranous nephropathy in two Chinese cohorts. Br J Biomed Sci. 2020;77:24–28.
Yoshikawa M, Asaba K. Single-nucleotide polymorphism rs4664308 in PLA2R1 gene is associated with the risk of idiopathic membranous nephropathy: A meta-analysis. Sci Rep. 2020;10:13119.
Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep. 2004;5:777–782.
Chocian G, Chabowski A, Zendzian-Piotrowska M, Harasim E, Łukaszuk B, Górski J. High fat diet induces ceramide and sphingomyelin formation in rat’s liver nuclei. Mol Cell Biochem. 2010;340:125–131.
Chaurasia B, Tippetts TS, Mayoral Monibas R, Liu J, Li Y, Wang L, et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science. 2019;365:386–392.
المشرفين على المادة: 0 (Receptors, Phospholipase A2)
0 (PLA2R1 protein, human)
0 (Phospholipids)
تواريخ الأحداث: Date Created: 20240605 Date Completed: 20240605 Latest Revision: 20240608
رمز التحديث: 20240608
مُعرف محوري في PubMed: PMC11155565
DOI: 10.1097/HC9.0000000000000388
PMID: 38836837
قاعدة البيانات: MEDLINE
الوصف
تدمد:2471-254X
DOI:10.1097/HC9.0000000000000388